Trial Profile
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Oct 2012
Price :
$35
*
At a glance
- Drugs Abciximab (Primary) ; Reteplase (Primary)
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Therapeutic Use
- Acronyms GUSTO-V; GUSTOsex
- 05 Nov 2010 New trial record.